7 citations
,
August 2025 in “European Journal of Endocrinology” Long-term use of calcineurin inhibitors in transplant patients can cause hormone issues that can be managed with proper care.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
August 2008 in “European Neuropsychopharmacology” July 2022 in “Dermatologic Therapy” December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
33 citations
,
February 2021 in “Journal of Medicinal Chemistry” New compounds were developed that promote hair growth in mice.
July 2025 in “Journal of Investigative Dermatology” Baricitinib stops hair loss and promotes regrowth in alopecia areata.
January 2016 in “SHILAP Revista de lepidopterología” Switching from escitalopram to duloxetine helped stop hair loss.
6 citations
,
September 2017 in “Multiple Sclerosis and Related Disorders” Nail loss may be a side effect of the MS drug teriflunomide.
2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
September 2023 in “British Journal of Dermatology” Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
13 citations
,
July 2010 in “Drug safety” Lamotrigine may cause hair loss, affecting treatment compliance and health.
2 citations
,
January 1984 in “PubMed” Cimetidine does not significantly reduce hair growth in hirsutism.
58 citations
,
January 2003 in “Biological & Pharmaceutical Bulletin” Bombax ceiba stem bark extracts can lower blood pressure, but high doses can be toxic and lethal.
January 2023 in “Cutaneous and Ocular Toxicology” March 2026 in “Journal of Pharmaceutical Research” Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.
7 citations
,
April 2006 in “Experimental Neurology” Finasteride blocks deoxycorticosterone's anticonvulsant effects in infant rats, but indomethacin doesn't.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
January 2026 in “International Journal of Advanced Biochemistry Research” The dog improved significantly after treatment and needs lifelong thyroid medication.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
February 2026 in “Reports — Medical Cases Images and Videos” Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
April 2025 in “Pharmaceutics” Oil A formulation with Baricitinib shows promise for treating alopecia areata by promoting hair growth.
June 1987 in “Pediatric Neurology Briefs” Biotinidase deficiency can cause symptoms like sleepiness, hair loss, and seizures.
1 citations
,
March 2020 in “Journal of Pharmacological Sciences” Benzothiazepines like diltiazem reduce anxiety in mice by making neurosteroids.
30 citations
,
January 2024 in “Frontiers in Pharmacology” These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
3 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes” Low-dose Buserelin effectively reduces hirsutism with minimal side effects.
September 2023 in “Journal of The American Academy of Dermatology” The document's conclusion cannot be provided because the content is not available.